Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus |
| |
Authors: | Reap Elizabeth A Morris John Dryga Sergey A Maughan Maureen Talarico Todd Esch Robert E Negri Sarah Burnett Bruce Graham Andrew Olmsted Robert A Chulay Jeffrey D |
| |
Institution: | AlphaVax Inc., Research Triangle Park, NC 27709, USA. |
| |
Abstract: | We used a replication-incompetent, single-cycle, alphavirus replicon vector system to produce virus-like replicon particles (VRP) expressing the extracellular domain of human cytomegalovirus (CMV) glycoprotein B or a pp65/IE1 fusion protein. Efficient production methods were scaled to produce pilot lots and clinical lots of each alphavirus replicon vaccine component. The vaccine induced high-titered antibody responses in mice and rabbits, as measured by ELISA and CMV neutralization assays, and robust T-cell responses in mice, as measured by IFN-gamma ELISPOT assay. A toxicity study in rabbits showed no adverse effects in any toxicology parameter. These studies support clinical testing of this novel CMV alphavirus replicon vaccine in humans. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|